IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene ADAMTS13 Ensembl ENSG00000160323 Chromosome 9 Start 135276941 End 135314329
Description A disintegrin and metalloproteinase with thrombospondin motifs 13 Precursor (ADAMTS-13)(ADAM-TS 13)(ADAM-TS13)(EC 3.4.24.-)(von Willebrand factor-cleaving protease)(vWF-cleaving protease)(vWF-CP) [Source:UniProtKB/Swiss-Prot;Acc:Q76LX8]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 1366
     Entrez Gene : 11093
     UCSC : uc004cdv.3
     GeneCards : 1366
     RefSeq : NM_139025
     CCDS : CCDS6970.1
     Uniprot : Q76LX8
     Interpro : Q76LX8
     OMIM : 604134
     GeneTests : ADAMTS13
     CGAP : ADAMTS13
     PMID : 11557746

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  220208_at  -0.14  5.38e-2  7.43e-2  -2.27  3.50e-38  6.59e-38
 HG_U133_Plus2  220208_at  -0.30  2.77e-2  5.03e-2  -0.48  8.27e-3  1.37e-2
 HG_U133_Plus2  223844_at  0.06  7.44e-1  8.02e-1  0.42  3.20e-2  4.75e-2
 Agilent_HS_21.6K  19412  -0.06  3.06e-1  4.94e-1  -0.09  5.96e-2  1.41e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  220208_at  0.08  8.37e-1  9.86e-1  -0.01  9.75e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U133A - 220208_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 220208_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 223844_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 19412    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
adamts13 colon carcinoma High levels of ADAMTSs transcripts were also observed in some tumor biopsies and cells lines, including osteosarcomas (ADAMTS19), melanoma and colon carcinoma cells (ADAMTS13). 11867212 Human
adamts13 tumor High levels of ADAMTSs transcripts were also observed in some tumor biopsies and cells lines, including osteosarcomas (ADAMTS19), melanoma and colon carcinoma cells (ADAMTS13). 11867212 Human
adamts13 melanoma High levels of ADAMTSs transcripts were also observed in some tumor biopsies and cells lines, including osteosarcomas (ADAMTS19), melanoma and colon carcinoma cells (ADAMTS13). 11867212 Human
vwf-cp tumors Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. von Willebrand factor (vWF) multimeric pattern and von Willebrand factor-cleaving protease activity (vWF-cp) were studied using plasmas from patients with 12091044 Human
von willebrand factor-cleaving protease tumors Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. von Willebrand factor (vWF) multimeric pattern and von Willebrand factor-cleaving protease activity (vWF-cp) were studied using plasmas from patients with 12091044 Human
vwf-cp tumors Deficiency of highly polymeric forms of vWF was observed in plasmas from 7 of 11 patients tested. vWF-cp activity was deficient in plasma samples of six patients with advanced stage-malignant tumors (ranging from 6% to 30% activity of normal plasma), wher 12091044 Human
vwf-cp colon cancer To further analyze the relevance of this enzymatic activity in metastatic diagnosis, a study of vWF-cp activity was conducted in 17 patients with colon cancer, and it was shown that deficiency of vWF-cp was associated with the progression of the disease. 12091044 Human
von willebrand factor-cleaving protease metastatic cancer We report a case of cancer-related thrombotic microangiopathy secondary to disseminated metastatic cancer with undetectable serum Von Willebrand factor-cleaving protease activity and no evidence of serum inhibitory antibody. 12182911 Human
ttp advanced colorectal cancer PATIENTS AND METHODS: The ratio of TTP during first and second-line therapy, identified as the growth modulation index (GMI), was determined in 34 patients with advanced colorectal cancer. 11300322 Human
von willebrand factor-cleaving protease malignant tumours Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. 11328288 Human
ttp neoplasms Microangiopathic haemolytic anaemia (MAHA) with thrombocytopenia in patients with metastasizing neoplasms is clinically similar to TTP, however, the pathogenesis of the condition is unclear. 11328288 Human
adamts13 cancer ADAMTS13 level at presentation was lower than 5% in 16 of 20 patients with idiopathic TTP and in none of 17 patients with TTP associated with hematopoietic stem cell transplantation, cancer, drugs, or pregnancy (P <.00001). 14982878 Human
ttp leukaemia TTP and "dUMP" pools have been measured in mouse L1210 leukaemia cells treated with the quinazoline antifolates ZD1694 (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl )-N-methylamine]-2-thenoyl)-L-glutamic acid) and CB30900 (N-[N-[4-[N 8787544 Human
adamts13 metastatic cancer Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy. 12714826 Human
adamts13 metastatic cancers Despite similarity in clinical manifestation, microangiopathic hemolysis in patients with metastatic cancers may not be caused by ADAMTS13 deficiency and the role of plasma exchange in such patients should be reevaluated. 12714826 Human
adamts-13 tumors Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). 12681973 Human
adamts-13 tumors RESULTS: Patients with disseminated tumors had lower mean plasma levels of ADAMTS-13 than those with localized tumors, but these differences did not reach the level of statistical significance (p=0.059). 12681973 Human
adamts-13 tumors The level of ADAMTS-13 was significantly lower in patients with localized tumors than in controls ( p = 0.0003 ), but higher than in patients with disseminated disease (p=0.0001 vs controls). 12681973 Human
adamts-13 malignancy INTERPRETATION AND CONCLUSIONS: Malignancy, whether localized or disseminated, is another condition associated with low ADAMTS-13 levels not accompanied by signs and symptoms of TTP and other thrombotic microangiopathies. 12681973 Human
adamts-13 prostate tumors ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. 14644076 Human
adamts-13 metastasis ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. 14644076 Human
adamts-13 malignancy ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. 14644076 Human
adamts-13 malignant tumors Impaired Von Willebrand factor cleaving activity of ADAMTS-13 was demonstrated in patients with metastasizing and malignant tumors. 14644076 Human
adamts-13 prostate tumors To investigate the relevance of ADAMTS-13 for tumor progression, we determined ADAMTS-13 activity and VWF:Ag in 80 patients with various malignancies: 30 patients with benign brain tumors, 30 patients with malignant brain tumors, 10 patients with local pr 14644076 Human
adamts-13 benign brain tumors To investigate the relevance of ADAMTS-13 for tumor progression, we determined ADAMTS-13 activity and VWF:Ag in 80 patients with various malignancies: 30 patients with benign brain tumors, 30 patients with malignant brain tumors, 10 patients with local pr 14644076 Human
adamts-13 tumor To investigate the relevance of ADAMTS-13 for tumor progression, we determined ADAMTS-13 activity and VWF:Ag in 80 patients with various malignancies: 30 patients with benign brain tumors, 30 patients with malignant brain tumors, 10 patients with local pr 14644076 Human
adamts-13 malignant brain tumors To investigate the relevance of ADAMTS-13 for tumor progression, we determined ADAMTS-13 activity and VWF:Ag in 80 patients with various malignancies: 30 patients with benign brain tumors, 30 patients with malignant brain tumors, 10 patients with local pr 14644076 Human
adamts-13 prostate tumors We found mild ADAMTS-13 deficiency in 17/80 tumor patients, but there was no significant difference in ADAMTS-13 activity between the age- and sex-matched patients with benign and malignant brain tumors nor between the age matched patients with local and 14644076 Human
adamts-13 tumor We found mild ADAMTS-13 deficiency in 17/80 tumor patients, but there was no significant difference in ADAMTS-13 activity between the age- and sex-matched patients with benign and malignant brain tumors nor between the age matched patients with local and 14644076 Human
adamts-13 malignant brain tumors We found mild ADAMTS-13 deficiency in 17/80 tumor patients, but there was no significant difference in ADAMTS-13 activity between the age- and sex-matched patients with benign and malignant brain tumors nor between the age matched patients with local and 14644076 Human
adamts-13 or malignancy Our data are hence in variance to previous studies, which found a distinct inverse correlation between ADAMTS-13 activity and level of metastasis and/or malignancy in diverse cancer-types. 14644076 Human
adamts-13 metastasis Our data are hence in variance to previous studies, which found a distinct inverse correlation between ADAMTS-13 activity and level of metastasis and/or malignancy in diverse cancer-types. 14644076 Human
adamts13 osteosarcomas High levels of ADAMTSs transcripts were also observed in some tumor biopsies and cells lines, including osteosarcomas (ADAMTS19), melanoma and colon carcinoma cells (ADAMTS13). 11867212 Human
adamts13 cancer ADAMTS proteins have recently gained attention with the discovery of their role in a variety of diseases, including tissue and blood disorders, cancer, osteoarthritis, Alzheimer's and the genetic syndromes Weill-Marchesani syndrome (ADAMTS10), thromb 15693998 Human
ttp tumor OBJECTIVES: We developed and established a new dose-finding system, the individualized maximum repeatable dose (iMRD), suitable to induce prolonged TTP rather than tumor shrinkage. 15782095 NA
ttp non-small cell lung cancer OBJECTIVE: To study serum DNA concentration in patients diagnosed as having advanced Non-Small Cell Lung Cancer (NSCLC) and to evaluate its relationship with age, histology, stage, response, time-to-progression (TTP), and survival. 15899220 NA
ttp nsclc OBJECTIVE: To study serum DNA concentration in patients diagnosed as having advanced Non-Small Cell Lung Cancer (NSCLC) and to evaluate its relationship with age, histology, stage, response, time-to-progression (TTP), and survival. 15899220 NA
vwf-cp malignancy Partial deficiency of VWF-cp in metastasizing malignancy has recently been reported in patients without MAHA. 11328288 Human
vwf-cp tumors Moreover, the serum vWF-cp activities were compared between the patients with TTP and those with tumors. 15198879 Human
vwf-cp malignant tumors Although the vWF-cp activities in patients with benign and malignant tumors were also decreased (P < 0.03 and P < 0.001, respectively), they were relatively high in comparison with that of TTP patients (P < 0.001). 15198879 Human
vwf-cp tumors The vWF-cp activity in patients with TTP was markedly lower than those of patients with tumors. 15198879 Human
vwf-cp solid tumors The results showed that the residual collagen binding assay was sensitive enough to measure the serum or plasma vWF-cp activity in 87 health individuals, 79 patients suffering from TTP and solid tumors. 15631648 Human
vwf-cp malignant tumors The serum and plasma vWF-cp activity in health individuals was (79.47 +/- 10.78)% (n = 53) and (78.79 +/- 9.17)% (n = 30), respectively, whereas the vWF-cp activity in patients with TTP, benign and malignant tumors was significantly decreased (P values we 15631648 Human
vwf-cp solid tumors It is concluded that the vWF-cp activity in plasma or serum of patients with TTP and solid tumors markedly decrease, especially in patients with TTP. 15631648 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.